Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, July 9, 2012 – Read More
Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan
PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Read More
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
Agendia’s Microarray-based Gene Expression Profile Provides Critical Additional Information for Read More
Agendia Raises $65 Million in a Private Round of Equity Financing
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 31, 2012 – Read More
Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
AMSTERDAM, THE NETHERLANDS, and IRVINE, CA, May 29, 2012 – Read More
A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response
PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Read More
RASTER: First-Ever Prospective Diagnostic Study in Breast Cancer
RASTER Five-Year Follow-Up Data Indicates Chemotherapy May Be Safely Withheld Read More
Agendia Wins 2011 Scrip Award for “Best Partnership Alliance”
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, FEBRUARY 29, 2012 – Read More
Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode
PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb Read More
Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance
PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub Read More
